The recent excellent report of metastases at the time of death by the
Collaborative Ocular Melanoma Study (COMS) ends with a discussion of guidelines
for evaluating future patients.1 This is
an important issue because follow-up protocols vary from no routine screening
to computed tomography twice a year, because early chemoimmunotherapy might
be most effective, and because patients enrolled in trials should be comparable.
A widely accepted review protocol would be helpful in these respects.
Eskelin S, Kivelä T. Imaging to Detect Metastases From Malignant Uveal Melanoma. Arch Ophthalmol. 2002;120(5):676. doi: